Advertisement

Topics

MEBIAS Discovery LLC Company Profile

16:12 EDT 18th August 2018 | BioPortfolio

MEBIAS, an emerging leader in the field of biased agonism GPCR drug discovery, was founded by three highly experienced drug discovery scientists, formerly of Merck and Johnson & Johnson. MEBIAS has developed a platform to discover next-generation GPCR drugs that avoid the on-target side effects of earlier generations of compounds, which historically signal through both the G-protein as well as the beta-arrestin pathways. The platform is established on the principle that compounds signaling through either the G-protein or the beta-arrestin pathway can be efficacious with fewer or no side effects. At the core of MEBIAS’ know-how are two specialized technologies: native GPCR purification and protein nuclear magnetic resonance. This know-how allows MEBIAS to achieve sensitivity unmatched by cell assays alone. The Company’s lead program has produced proprietary mu opioid agonists designed to achieve analgesia without respiratory depression, constipation, and addiction potential seen in opioids on the market today. An additional internal discovery program will be initiated by the end of 2017. Areas of focus are neuroscience/pain, metabolic, gastroparesis, and inflammatory disorders.


News Articles [288 Associated News Articles listed on BioPortfolio]

Integrated lead discovery: An evolving toolbox

(SLAS (Society for Laboratory Automation and Screening)) A new SLAS Discovery review article by GlaxoSmithKline researchers in the US and UK offers an informative guide to the established and emerging...

High-Throughput Flow Cytometry in Drug Discovery

NewsA new special issue of SLAS Discovery reflects examples of the recent groundswell of creative new applications for high-throughput flow cytometry (HTFC) in drug discovery.

The Current issue of “The view from here” is concerned with Allosterism in Drug Discovery.

The topic of this month’s newsletter from Drug Discovery Today is “Allosterism in Drug Discovery”.

The Current issue of “The view from here” is concerned with nanoscience in drug discovery.

The topic of this month’s newsletter from Drug Discovery Today is “nanoscience in drug discovery”

BioAscent Discovery secures £1.6 million in funding for growth

Provider of integrated drug discovery services, BioAscent Discovery, has secured funding worth £1.6 million from Maven Capital Partners, which it will use for growth through its offering of integrate...

Eisai accelerates dementia drug discovery research

Eisai is launching a special dementia discovery centre to boost development of next-generation medicines targeting forms of the condition, including Alzheimer’s disease. The new Center for Genetic...

Pharmacophore modeling and applications in drug discovery: challenges and recent advances

The most downloaded article from Drug Discovery Today in Q2 2010 was by Sheng-Yong Yang and deals with the application of pharmacophore modeling to drug discovery.

InterMed Discovery: The World's Largest Natural Product Library

In this interview Fintan Walton talks to Mr Erik Metz, Head of Business Development at InterMed Discovery - a Natural Product lead discovery company from Dortmund, Germany. Erik Metz explains how Inte...

PubMed Articles [504 Associated PubMed Articles listed on BioPortfolio]

Translation of innovative chemistry into screening libraries: an exemplar partnership from the European Lead Factory.

The identification of high-quality starting points for drug discovery is an enduring challenge in medicinal chemistry. Yet, the chemical space explored in discovery programmes tends be limited by the ...

The continuing effect of the discovery of IgE by Kimishige Ishizaka.

Sadly, Kimi Ishizaka died on July 6, 2018. I would like to take the opportunity to consider his role in the discovery of IgE and the effect of that discovery. All of us owe an enormous debt to those w...

Filling the drug discovery gap: is high-content screening the missing link?

In recent years, questions about the sustainability of the current drug discovery process have triggered a revival of interest in phenotypic drug discovery approaches. This trend has clearly been ampl...

Computational Toxicology and Drug Discovery.

The use of computational toxicology methods within drug discovery began in the early 2000s with applications such as predicting bacterial mutagenicity and hERG inhibition. The field has been continuou...

Renovation as innovation: is repurposing the future of drug discovery research?

Clinical Trials [175 Associated Clinical Trials listed on BioPortfolio]

Discovery Elbow Multi-Center Prospective Study

The purpose of this prospective clinical trial is to document the performance and clinical outcomes of Biomet Discovery Elbow.

A Clinical Investigation of the Discovery™ Elbow System

The purpose of this study is to perform a five-year, multi-center prospective evaluation of the Discovery™ Elbow System for outcome and durability. Relief of pain and restoration of fun...

Endometriosis Biomarker Discovery Study

This is a prospective, Single time point, discovery study intending to identify biomarkers that can differentiate endometriosis from other underlying reasons for pelvic pain. Patients unde...

Protein Biomarker Discovery and Validation in Chronic Obstructive Pulmonary Disease (COPD) And Asthma

The purpose of the study is to better understand the function of asthma and COPD, and response to therapy. There are two Phases to this study broken into two arms. In Phase I, our propose ...

Biologic Basis of Liver Cancer From Chronic Hepatitis B

The focus of the study is to identify viral factors and host immune responses that differentiate HBV-related HCC patients from HBV patients who have not progressed to HCC. To that end, the...

Companies [1100 Associated Companies listed on BioPortfolio]

MEBIAS Discovery LLC

MEBIAS, an emerging leader in the field of biased agonism GPCR drug discovery, was founded by three highly experienced drug discovery scientists, formerly of Merck and Johnson & J...

Discovery Health

Discovery Health Media includes the Discovery Health and FitTV television networks and online assets, including www.discoveryhealth.com, as well as its Continuing Medical Education (CME) business and ...

Argenta Discovery Ltd.

Argenta Discovery is a privately held drug discovery company, applying its integrated medicinal chemistry, biology, ADMET and CADD expertise to drive drug discovery programmes. Argenta has a successfu...

Pyxis Discovery B.V.

The ambition of Pyxis Discovery is to be the preferred chemistry service provider for companies that are active in small molecule drug discovery. Pyxis Discovery's Smart approach of designing and ...

Med Discovery SA

Med Discovery’s mission is the discovery and development of highly specific protein drugs to treat uro-genital cancers. By combining biological drug discovery expertise with a strong in-house knowle...

More Information about "MEBIAS Discovery LLC" on BioPortfolio

We have published hundreds of MEBIAS Discovery LLC news stories on BioPortfolio along with dozens of MEBIAS Discovery LLC Clinical Trials and PubMed Articles about MEBIAS Discovery LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MEBIAS Discovery LLC Companies in our database. You can also find out about relevant MEBIAS Discovery LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Corporate Database Quicklinks



Searches Linking to this Company Record